Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’
In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases As of August 2023, Renovaro has raised total cash of $82.7 million The company’s IP portfolio covering gene and gene-modified…